THERAPY WITH MONOCLONAL ANTIBODIES IN THE TREATMENT OF AUTOIMMUNE DISEASES: PROGRESS AND PROSPECTS

Abstract

Monoclonal antibody therapy revolutionizes the treatment of autoimmune diseases, offering an innovative and effective therapeutic approach. This article reviews advances and prospects in this area, highlighting results that demonstrate its effectiveness, customization, development of multifunctional therapies, and a renewed commitment to long-term safety. The clinical efficacy of monoclonal antibody therapies has been consistently observed, with the ability to achieve symptomatic and functional remission in severe autoimmune diseases. The modulation of inflammatory and immunological pathways allowed a more effective control of the autoimmune response, alleviating symptoms and delaying the progression of the disease. Treatment customization, based on biomarkers and specific targets, provided an adapted therapeutic approach, maximizing clinical results. The development of multifunctional therapies emerged as an innovative approach, combining different mechanisms of action in a single therapeutic molecule. This has expanded the ability to address multiple pathological aspects, increasing therapeutic efficacy. Long-term monitoring and safety assessment ensured the sustainability of therapeutic benefits. Future prospects include the continuous identification of new targets and biomarkers, improving therapeutic specificity. The integration of monoclonal antibody therapies into combination and personalized approaches promises to take clinical outcomes to new heights. In short, monoclonal antibody therapy redefines the treatment of autoimmune diseases. Efficacy, personalization, safety and innovation highlight its essential role in the therapeutic arsenal. As advances and discoveries continue to shape this field, monoclonal antibody therapy remains at the forefront of precision medicine and the treatment of autoimmune diseases.